Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Gastroenterology

Categorizing Your Symptoms: The IBS Subtypes

At a Glance

Irritable bowel syndrome (IBS) is categorized into four subtypes—IBS-C (constipation), IBS-D (diarrhea), IBS-M (mixed), and IBS-U (unclassified)—based on the Bristol Stool Form Scale. Accurately identifying your subtype is essential for choosing the right medications and dietary strategies.

Once a diagnosis of Irritable Bowel Syndrome (IBS) is confirmed, the next vital step is determining your subtype. IBS is not a “one-size-fits-all” condition; the way your body processes food and waste dictates which treatments will be most effective for you [1]. Doctors use a tool called the Bristol Stool Form Scale (BSFS) to classify your symptoms into one of four specific categories [2].

The Bristol Stool Form Scale

The BSFS is a medical chart that breaks stool into seven types based on appearance and consistency:

  • Types 1–2: Hard, lumpy, or “nut-like” stools (indicating constipation) [3].
  • Types 3–4: Smooth, sausage-like, or cracked stools (considered “normal” or ideal).
  • Types 5–7: Soft blobs, ragged edges, or entirely liquid stools (indicating diarrhea) [3].

Defining the Four Subtypes

According to the Rome IV criteria, your subtype is determined by your stool form on days when you have at least one abnormal bowel movement [1].

Subtype Predominant Stool Pattern
IBS-C (Constipation) >25% of stools are Types 1–2; <25% are Types 6–7 [1].
IBS-D (Diarrhea) >25% of stools are Types 6–7; <25% are Types 1–2 [1].
IBS-M (Mixed) >25% of stools are Types 1–2 AND >25% are Types 6–7 [1].
IBS-U (Unclassified) Symptoms meet IBS criteria, but stool patterns do not fit the above [2].

Why Subtyping Matters for Treatment

Accurately identifying your subtype is clinically necessary because it serves as the roadmap for your treatment plan. Using a treatment meant for one subtype on another can lead to ineffective results or worsening symptoms [4].

  • Targeted Medications: For IBS-C, doctors often use secretagogues (medicines that prompt the intestines to secrete fluid to soften stool, like linaclotide), which work by drawing water into the intestines to speed up transit [4][5]. For IBS-D, treatments may include rifaximin, an antibiotic that modulates gut bacteria, or medications that slow down intestinal movement [6][7].
  • Personalized Approaches: For IBS-M, the challenge is treating both extremes. Doctors may focus on “neuromodulators” that address the underlying nerve sensitivity (visceral hypersensitivity) common to all subtypes, or recommend dietary strategies to stabilize stool form before adding harsh laxatives or anti-diarrheals [8][9].
  • Dietary Strategy: While a low-FODMAP diet is a common first-line recommendation for all subtypes to reduce pain and bloating, the specific types of fiber or lifestyle changes you need will depend heavily on whether your primary struggle is constipation or diarrhea [10][11].

Because your subtype can sometimes change over time, keeping a stool diary using the Bristol scale can help you and your doctor adjust your management strategy as your body shifts [12][13].

Common questions in this guide

How do doctors determine my IBS subtype?
Doctors use the Bristol Stool Form Scale to evaluate your bowel movements on days you have abnormal digestion. Your subtype is based on the percentage of hard, lumpy stools versus loose, watery stools you experience.
What is the difference between IBS-C and IBS-D?
IBS-C is constipation-predominant, meaning most of your abnormal stools are hard and lumpy. IBS-D is diarrhea-predominant, which is characterized primarily by loose or watery stools.
Why does my IBS subtype matter for treatment?
Identifying your specific subtype ensures you receive the correct targeted therapies. Using a treatment meant for constipation when you have diarrhea, or vice versa, can be ineffective or actively worsen your symptoms.
How is IBS-M (Mixed) treated?
Treating mixed IBS requires balancing therapies for both constipation and diarrhea. Doctors often focus on dietary strategies to stabilize stool form or use medications called neuromodulators that calm overall gut nerve sensitivity.
Can my IBS subtype change over time?
Yes, your predominant stool pattern can shift over time. Keeping a daily stool diary can help you track these changes so your doctor can safely adjust your treatment plan as needed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my stool patterns over the last few months, which IBS subtype do I fall into?
  2. 2.How does my specific subtype change the medication options you are considering?
  3. 3.If I have IBS-M (Mixed), how do we balance treating both constipation and diarrhea without making either one worse?
  4. 4.Is it possible for my IBS subtype to change over time, and what should I monitor if it does?
  5. 5.Are there specific types of fiber or dietary changes that are better for my particular subtype?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Pros and Cons While Looking Through an Asian Window on the Rome IV Criteria for Irritable Bowel Syndrome: Pros.

    Ghoshal UC

    Journal of neurogastroenterology and motility 2017; (23(3)):334-340 doi:10.5056/jnm17020.

    PMID: 28672432
  2. 2

    Management of Irritable Bowel Syndrome: Physician-Dietitian Collaboration.

    Ireton-Jones C, Weisberg MF

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2020; (35(5)):826-834 doi:10.1002/ncp.10567.

    PMID: 32786046
  3. 3

    Relationship between Stool Form and Quality of Life in Patients with Chronic Constipation: An Internet Questionnaire Survey.

    Ohkubo H, Yoshihara T, Misawa N, et al.

    Digestion 2021; (102(2)):147-154 doi:10.1159/000502815.

    PMID: 31574514
  4. 4

    Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.

    Rao SSC, Xiang X, Yan Y, et al.

    Alimentary pharmacology & therapeutics 2020; (51(12)):1332-1341 doi:10.1111/apt.15772.

    PMID: 32406112
  5. 5

    Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.

    Lembo AJ, Chey WD, Harris LA, et al.

    The American journal of gastroenterology 2024; (119(5)):937-945 doi:10.14309/ajg.0000000000002685.

    PMID: 38294158
  6. 6

    Rifaximin's therapeutic spectrum: approved indications and experimental insights into emerging uses.

    Palenca I, Franzin SB, Pesce M, et al.

    Pharmacological reports : PR 2026; (78(3)):627-640 doi:10.1007/s43440-026-00830-0.

    PMID: 41729463
  7. 7

    Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.

    Pimentel M

    Alimentary pharmacology & therapeutics 2016; (43 Suppl 1()):37-49 doi:10.1111/apt.13437.

    PMID: 26618924
  8. 8

    Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M).

    Nee J, Lembo A

    Alimentary pharmacology & therapeutics 2021; (54 Suppl 1()):S63-S74 doi:10.1111/apt.16625.

    PMID: 34927757
  9. 9

    A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome.

    Nulsen B, LeBrett W, Drossman DA, Chang L

    Alimentary pharmacology & therapeutics 2021; (54(3)):281-291 doi:10.1111/apt.16467.

    PMID: 34148256
  10. 10

    Diet, nutraceuticals, and lifestyle interventions for the treatment and management of irritable bowel syndrome.

    Memel ZN, Shah ND, Beck KR

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2025; (40(5)):1013-1030 doi:10.1002/ncp.11307.

    PMID: 40346863
  11. 11

    Dietary Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAPs) and Gastrointestinal Disease.

    Vakil N

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2018; (33(4)):468-475 doi:10.1002/ncp.10108.

    PMID: 29870082
  12. 12

    Stool Consistency: Looking Beyond the Bristol Stool Form Scale.

    Vork L, Wilms E, Penders J, Jonkers DMAE

    Journal of neurogastroenterology and motility 2019; (25(4)):625 doi:10.5056/jnm19086.

    PMID: 31587553
  13. 13

    Modest Conformity Between Self-Reporting of Bristol Stool Form and Fecal Consistency Measured by Stool Water Content in Irritable Bowel Syndrome and a FODMAP and Gluten Trial.

    Nordin E, Hellström PM, Brunius C, Landberg R

    The American journal of gastroenterology 2022; (117(10)):1668-1674 doi:10.14309/ajg.0000000000001942.

    PMID: 36087104

This page provides information on IBS subtypes and the Bristol Stool Form Scale for educational purposes. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a healthcare provider for personalized care.

Get notified when new evidence is published on irritable bowel syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.